License Agreements (Details Narrative) - USD ($) |
12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
May 17, 2022 |
Jun. 16, 2021 |
Oct. 06, 2020 |
Aug. 23, 2020 |
Aug. 19, 2020 |
Mar. 19, 2018 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Jan. 25, 2024 |
Jan. 22, 2024 |
Jan. 21, 2024 |
|
| Common stock, shares issued | 1,291,000 | 806,774 | |||||||||
| Stock Issued During Period, Value, New Issues | $ 6,352,077 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member] | |||||||||||
| Stock Issued During Period, Shares, Acquisitions | 14,931 | ||||||||||
| Stock Issued During Period, Value, New Issues | $ 8,000,000.0 | ||||||||||
| Subsequent Event [Member] | |||||||||||
| Common stock, shares issued | 1,291,000 | 24,706,474 | |||||||||
| License Agreement [Member] | Subsequent Event [Member] | |||||||||||
| Common stock, shares issued | 5,000 | ||||||||||
| License Agreement [Member] | Elion Oncology [Member] | |||||||||||
| Common Stock, Capital Shares Reserved for Future Issuance | 5,000 | ||||||||||
| Expense and related liability | $ 189,000 | ||||||||||
| Performance of milestone conditions, description | including dosing a first patient with a product in a Phase 2 or 3 clinical trial within 48 months from when we entered into the License Agreement. We are currently on track to dose our first patient in a Phase 2 clinical trial on or before October 2, 2024. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and a 90-day opportunity to cure such breach (which is shortened to 15 days for a payment breach). | ||||||||||
| Stock Issued During Period, Shares, Acquisitions | 5,000 | ||||||||||
| License Agreement [Member] | Elion Oncology [Member] | First Milestone [Member] | |||||||||||
| Milestone payment description | shares of our common stock on each of the first and second anniversary dates of the Elion License Agreement. | ||||||||||
| License Agreement [Member] | Ocuphire Pharma Inc [Member] | |||||||||||
| Stock Issued During Period, Shares, Acquisitions | 2,235 | ||||||||||
| Cash paid under license agreement | $ 200,000 | ||||||||||
| Liabilities Assumed | $ 66,583 | ||||||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | |||||||||||
| Stock Issued During Period, Shares, Acquisitions | 31,250 | ||||||||||
| Milestone payments, description | As additional consideration, we will pay Aposense development and regulatory milestone payments (up to $3.0 million per milestone) upon the achievement of certain milestones, which primarily consist of having a drug indication approved by a regulatory authority in the United States or another country. In addition, we will pay Aposense one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter. | ||||||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | Maximum [Member] | |||||||||||
| Development and regulatory milestone payments | $ 3,000,000.0 | ||||||||||
| License Agreement [Member] | Yuhan Corporation [Member] | |||||||||||
| Performance of milestone conditions, description | specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product by August 19, 2024. | ||||||||||
| Stock Issued During Period, Shares, Acquisitions | 25,000 | ||||||||||
| Milestone payments, description | In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter. | ||||||||||
| License Agreement [Member] | Yuhan Affiliate [Member] | Underwritten Public Offering [Member] | October 2020 [Member] | |||||||||||
| Shares issued in connection with our 2020 offering | 37,500 | ||||||||||
| Proceeds from offering | $ 3,000,000 | ||||||||||